UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.38 Million Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 11.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 265,210 shares of the biopharmaceutical company’s stock after purchasing an additional 27,420 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.25% of Revance Therapeutics worth $1,376,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in RVNC. Certuity LLC bought a new stake in shares of Revance Therapeutics in the 2nd quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC bought a new stake in Revance Therapeutics in the second quarter valued at approximately $33,000. Hsbc Holdings PLC bought a new stake in Revance Therapeutics in the second quarter valued at approximately $38,000. Nisa Investment Advisors LLC raised its holdings in Revance Therapeutics by 2,167.5% in the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 18,077 shares during the period. Finally, FORA Capital LLC bought a new position in shares of Revance Therapeutics during the third quarter worth $54,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analysts Set New Price Targets

RVNC has been the topic of several recent analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. HC Wainwright reiterated a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a report on Friday, November 8th. Mizuho lowered their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. StockNews.com began coverage on shares of Revance Therapeutics in a report on Thursday, December 12th. They set a “hold” rating on the stock. Finally, Barclays reiterated an “equal weight” rating and issued a $7.00 price target (down previously from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.96.

Revance Therapeutics Stock Down 0.6 %

NASDAQ RVNC opened at $3.07 on Wednesday. Revance Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $9.74. The firm’s 50 day moving average is $4.47 and its 200-day moving average is $4.49. The company has a market capitalization of $322.05 million, a PE ratio of -1.59 and a beta of 0.81.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. As a group, sell-side analysts expect that Revance Therapeutics, Inc. will post -1.57 EPS for the current year.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.